Pantoprazole (sodium hydrate)

Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI)^[1]. Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H⁺/K⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142)^[3][4]. In Vitro:Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells^[1].
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H⁺-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium^[2] In Vivo:Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin^[1].
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats^[4].